Eliana Witchell RD - Evidence-Based Nutrition
Access

Insurance and Coverage for GLP-1 Medications

Reference starting points — verify with your own insurer

Reviewed by Eliana Witchell, MSc, RD, CDELast reviewed: Version 1.0.0

Coverage varies widely. Canadian military: BMI 40, or BMI 37 + comorbidities, or post-cardiac event. Canadian private and public insurance: variable by plan and province. US commercial insurance: diabetes indications covered more readily than weight management. Verify with your specific insurer and prescriber — do not assume.

Insurance coverage for GLP-1 medications varies significantly by jurisdiction, insurer, and indication. Canadian Armed Forces members have specific BMI-based coverage rules. Canadian provincial plans vary; private insurance varies even more. US coverage depends on insurer, state, plan type, and whether the medication is prescribed for type 2 diabetes (generally covered more readily) or weight management (variable). This page provides reference starting points, not promises — verify current coverage with your prescriber and insurer. Educational content. Not individualized Medical Nutrition Therapy.

Canadian reference points

  • Canadian Armed Forces: coverage typically at BMI 40, or BMI 37 with comorbidities, or post-cardiac event
  • Provincial formularies: variable. Type 2 diabetes indications generally covered more readily than weight-management indications
  • Private insurance: individual and employer plans vary widely. Prior authorization is common
  • First Nations and Inuit Health Branch: coverage varies by medication and indication

US reference points

  • Commercial insurance: diabetes indications (Ozempic, Mounjaro) generally covered more readily than weight management (Wegovy, Zepbound); prior authorization and step-therapy common
  • Medicare: coverage has tightened; verify with your plan administrator
  • Medicaid: varies by state; check your state Medicaid formulary
  • Manufacturer savings cards: often help when commercially insured; typically do not apply to government-insured patients

What to do about a denial

  1. Appeal with your prescriber. Documented medical necessity and prior failed approaches frequently succeed on appeal.
  2. Try a different medication in the class that your plan covers. Intra-class alternatives often exist.
  3. Pursue manufacturer assistance programs if eligible.
  4. Pay out-of-pocket if budget supports 12-month commitment.
  5. Delay treatment while you save or advocate for coverage change. Address non-medication approaches in the interim.

When to seek individualized support

Coverage-aware planning can shape which medication you try first and what the contingency plan looks like. If you live in Ontario, British Columbia, or Nova Scotia, individualized Medical Nutrition Therapy can work alongside your prescriber and insurer process. Eliana's practice does not submit insurance authorizations for GLP-1 medications — that belongs with your prescriber — but can support the rest of the plan.

Common questions

How is coverage decided?
Insurers typically require evidence of medical necessity: clinical indication (type 2 diabetes or qualifying obesity), documented prior failed approaches where applicable, BMI threshold, and sometimes documented comorbidities. Your prescriber submits a prior authorization with the clinical justification.
What is Canadian military coverage?
For Canadian Armed Forces members, coverage for GLP-1 medications for weight management typically requires BMI 40, or BMI 37 with comorbidities, or post-cardiac event. Oral GLP-1 options may expand access for deployable members because they do not require refrigeration. Specific policy details change — confirm with your medical officer.
What about Canadian provincial coverage?
Varies by province. Some provincial formularies cover GLP-1 medications for type 2 diabetes readily but do not cover weight-management indications. Some cover Saxenda more readily than newer medications. Check your provincial formulary and your prescriber's familiarity with the process.
What about Canadian private insurance?
Even more variable. Individual and employer-sponsored plans have different rules. Many plans require prior authorization with specific clinical criteria. Some exclude weight-management indications entirely. Call the number on your insurance card and ask specifically about the medication and indication.
What about US coverage?
US insurance generally covers GLP-1 medications more readily for type 2 diabetes (Ozempic, Mounjaro) than for weight management (Wegovy, Zepbound). Prior authorization and step-therapy requirements are common. Medicare has been tightening coverage; Medicaid varies by state. Manufacturer copay cards can reduce out-of-pocket for commercially insured patients.
What if my insurance denies coverage?
Options: (1) Appeal with your prescriber. Documented medical necessity and prior failed approaches often succeed on appeal. (2) Try a different medication in the class that your plan does cover. (3) Pursue manufacturer assistance programs. (4) Pay out-of-pocket if the budget supports 12-month commitment. (5) Delay treatment and address non-medication approaches while saving or lobbying for coverage change.
What documentation should I bring to my prescriber?
Medical history relevant to the indication (diabetes labs, obesity history, cardiovascular risk factors), documented prior attempts at lifestyle or other weight-management approaches, any comorbidity documentation (sleep apnea, fatty liver, joint issues), and your insurance card. This gives your prescriber what they need to submit prior authorization.
Can I switch insurers to get coverage?
In rare cases this is financially rational — typically when an employer-sponsored plan covers GLP-1 medications for weight management and your current individual plan does not. Usually not worth it on a standalone basis; changing insurance affects your entire medical picture, not just GLP-1 access.
What if I move between jurisdictions mid-treatment?
Plan for coverage changes in advance. A US-to-Canada move or a move between Canadian provinces can disrupt treatment. Talk to your prescriber about continuity plans and whether a bridge prescription or supply is feasible.

Related in this cluster

References

  1. Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026. Published online April 10, 2026. (DOI)
  2. Practitioner case material: Eliana Witchell, MSc, RD, CDE. Clinical notes, 2023–2026. Anonymized.

Ready to go deeper?

If this page helped, the free Initial Consult Experience walks you through how Eliana approaches metabolic nutrition. Educational, self-directed, no credit card required.

Start Here First: Free Initial Consult ExperienceWhy This Is Different

Important Disclaimer: This program is for educational purposes only and does not replace individualized Medical Nutrition Therapy or medical care.

Personalized nutrition therapy services are available only in jurisdictions where Eliana Witchell, RD, CDE holds active licensure. Always consult with your healthcare provider before making changes to your diet, exercise, or medication regimen.

This page is for educational purposes only and does not replace individualized Medical Nutrition Therapy or medical care.